摘要
目的探讨阿托伐他汀预防心房颤动(房颤)复发的作用。方法选择频繁发作的特发性阵发性房颤患者54例,随机分成两组,Ⅰ组(仅给予胺碘酮治疗)和Ⅱ组(给予胺碘酮+阿托伐他汀治疗),随访1年,观察治疗前后C反应蛋白(CRP)变化及窦性心律维持率。结果治疗前后,Ⅰ组CR(Pmg/L)分别为3.21±0.13和3.14±0.12(P>0.05),Ⅱ组分别为3.23±0.11和1.16±0.10(P<0.05)。Ⅰ组和Ⅱ组的窦性心律维持率分别为56.34%和70.87%(P<0.05)。结论阿托伐他汀治疗可以减少阵发性房颤的复发,且与其抗炎作用相关。
Objective To investigate the preventive effect of atorvastatin on recurrence of paroxysmal atrial fibrillation. Methods 54 patients with idiopathic paroxysmal atrial fibrillation were randomly divided into two groups, Ⅰ group （treated with amiedarone） and Ⅱ group （treated with amiedarone and atorvastatin）. After 1 year follow-up, observe the change of C-reactive protein （CRP） and maintenance rate of sinus rhythm before and after treatment. Results Before and after treatment, CRP （mg/L） were 3.21±0.13 and 3.14±0.12 （P〉0.05） in Ⅰ group, 3.23±0.11 g; 1.16±0.10 （P〈0.05） in Ⅱ group. After treatment, maintenance rate of sinus rhythm of Ⅰ group and Ⅱ group was 56.34% VS 70.87% （P〈0.05）. Conclusions Atorvastatin may reduce recurrence of paroxysmal atrial fibrillation, which is related to the anti-inflammation of atorvastatin.
出处
《海南医学》
CAS
2007年第2期35-36,共2页
Hainan Medical Journal
关键词
胺碘酮
阿托伐他汀
心房颤动
Amiedarone
Atorvastatin
atrial fibrillation
